Sophia Genetics announced that Nigeria-based Syndicate Bio has signed on to implement MSK-Access powered with SOPHiA DDM. Syndicate Bio is the first lab in Africa to adopt the MSK-Access assay via the SOPHiA DDM Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, or MSK, and Syndicate Bio to advance health equity on a global scale.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- Sophia Genetics, Strand Life Sciences announce new strategic partnership
- Sophia Genetics announces first HRD customer in Canada
- SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
- Sophia Genetics price target raised to $8 from $7 at BTIG
- Sophia Genetics SA trading resumes
